USA Bio presentation, page-30

Not according to the first page of their 2019 annual report.

Antisense Therapeutics has world-wide exclusive licenses to exploit two antisense compounds (ATL1102 and ATL1103) for all disease indications via its partnership with Ionis Pharmaceuticals Inc (Ionis). As the leader in RNA- targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform that can treat diseases where no other therapeutic approaches have proven effective. Ionis has three approved antisense drugs and a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases and pulmonary diseases and cancer.The partnership with Ionis provides Antisense Therapeutics with access to Ionis’ antisense intellectual property and drug development expertise to facilitate the development and commercialisation of the Company's antisense compounds. In turn Ionis receives a share of product commercialisation proceeds received by Antisense Therapeutics.